MiR‐103‐3p targets the m<sup>6</sup>A methyltransferase METTL14 to inhibit osteoblastic bone formation
Zhongyang Sun, Han Wang, Yuxiang Wang, Guodong Yuan, Xin Yu, Hui Jiang, Qi Wu, Binkui Yang, Zebing Hu, Fei Shi, Xinsheng Cao, Shu Zhang, Ting Guo, Jianning Zhao
Abstract
Abstract Impaired osteoblast function is involved in osteoporosis, and microRNA (miRNA) dysregulation may cause abnormal osteoblast osteogenic activity. However, the influence of miRNA on osteoblast activity and the underlying mechanisms remain elusive. In this study, miR‐103‐3p was found to be negatively correlated with bone formation in bone specimens from elderly women with fractures and ovariectomized (OVX) mice. Additionally, miR‐103‐3p directly targeted Mettl14 to inhibit osteoblast activity, and METTL14‐dependent N 6 ‐methyladenosine (m 6 A) methylation inhibited miR‐103‐3p processing by the microprocessor protein DGCR8 and promoted osteoblast activity. Moreover, miR‐103‐3p inhibited bone formation in vivo, and therapeutic inhibition of miR‐103‐3p counteracted the decreased bone formation in OVX mice. Further, METTL14 was negatively correlated with miR‐103‐3p but positively correlated with bone formation in bone specimens from elderly women with fractures and OVX mice. Collectively, our results highlight the critical roles of the miR‐103‐3p/METTL14/m 6 A signaling axis in osteoblast activity, identifying this axis as a potential target for ameliorating osteoporosis.